Compare Mongodb Inc (MDB) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Repligen Corporation Common Stock — how do they compare? Mongodb Inc trades at $348.9 (market cap $30.05B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Mongodb Inc is far larger — about 2.7× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and Repligen Corporation Common Stock for 0 Days on average.
| MDB | RGEN | |
|---|---|---|
Market Cap | $30.05B | $11.14B |
Volume | 3,027,814 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $472.29 | $194.57 |
52-Week Low | $225.95 | $102.87 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $27.67B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $356.29, down 6.56% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly EPS beats, with Q3 2026 results pending. Revenue has grown from $874 million in 2022 to $2.01 billion in 2025, though net losses persist, narrowing to -$129 million in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
The outlook is cautiously optimistic, with a consensus price target of $456.76 implying 28% upside. Key opportunities include raised long-term revenue targets exceeding 20% growth and AI-driven product expansion. Risks involve continued net losses, high valuation multiples, and execution challenges amid leadership changes. Analyst consensus is strongly bullish with 80% buy ratings, but stock volatility may persist near-term.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
